6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Onconephrology: The intersections between the kidney and cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: not found
          • Article: not found

          Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.

            Tumor cells from malignancies of any type-carcinoma, sarcoma, lymphoma, leukemia-may cause systemic arteriolar and capillary obstructions. The high shear rates of blood passing through these obstructions result in fragmentation of the red cells and can cause severe anemia, described as microangiopathic hemolytic anemia (MAHA).The thrombi caused by these obstructions consume platelets and can lead to severe thrombocytopenia. MAHA (defined by fragmented red cells on the peripheral blood smear and evidence of hemolysis) and thrombocytopenia are the clinical features of syndromes described as thrombotic microangiopathies (TMAs). If a malignancy is not recognized as the cause of TMA, the diagnosis of thrombotic thrombocytopenic purpura (TTP) may be considered and plasma exchange, the essential treatment for TTP, may be initiated-a critical decision because this treatment carries a high risk of serious complications. This review describes the clinical features that should suggest a search for systemic malignancy as the cause of unexpected MAHA and thrombocytopenia. Recognition of a systemic malignancy is critical to the initiation of appropriate chemotherapy and avoidance of inappropriate use of plasma exchange treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients.

              Chronic renal failure is a common pathology. The high frequency of this disease in the general US population has been assessed in the NHANES III study. However, the frequency of chronic renal insufficiency among cancer patients remains unclear. 316 cancer patients were in a one-month study, included regardless of their pathology, treatment (antineoplastic drugs used or programmed to be used, pretreated, or no treatment), or any other criteria. Among the patients, 287 (90.8%) had normal serum creatinine levels (<110 micromol/l), i.e. a frequency of 9.2% for renal insufficiency in our population. However, when renal function was estimated by calculating creatinine clearance using the Cockcroft and Gault formula, 33% of the patients had an estimated GFR of less than 80 ml/min. Among these, 28% had a creatinine clearance ranging form 80 to 50 ml/min and 5% had a creatinine clearance of less than 50 ml/min. Renal insufficiency is frequent in cancer patients since almost one third of the patients present renal insufficiency. Furthermore, among patients with normal serum creatinine levels, one patient out of five has asymptomatic renal insufficiency. Therefore, it is of major importance that renal function be assessed by calculation of creatinine clearance using the Cockcroft and Gault formula in every patient, even when serum creatinine is within the normal range.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                Journal
                CA: A Cancer Journal for Clinicians
                CA A Cancer J. Clin.
                Wiley
                0007-9235
                1542-4863
                January 2021
                August 27 2020
                January 2021
                : 71
                : 1
                : 47-77
                Affiliations
                [1 ]Division of Nephrology University of Virginia School of Medicine Charlottesville Virginia
                [2 ]Division of Kidney Disease and Hypertension Zucker School of Medicine at Hofstra University Great Neck New York
                [3 ]Division of Nephrology. Medical University of South Carolina Charleston South Carolina
                [4 ]Division of Nephrology Yale University School of Medicine New Haven Connecticut
                Article
                10.3322/caac.21636
                32853404
                8bec522a-3873-4947-915e-d1060a71002b
                © 2021

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article